Same Active Ingredient, Different Brand

Several GLP-1 medications share an identical active ingredient but are sold under different brand names with different FDA-approved indications. Ozempic and Wegovy are both semaglutide — Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly, Wegovy for chronic weight management at doses up to 2.4 mg weekly. Mounjaro and Zepbound are both tirzepatide — Mounjaro for type 2 diabetes, Zepbound for weight management and obstructive sleep apnea. These brand distinctions are not cosmetic: they affect insurance coverage, prior-authorization approval, manufacturer savings-card eligibility, and the FDA-approved dosing schedule. Compounded versions sold through telehealth platforms add another layer of complexity. The guides below compare each same-drug, different-brand pair on approved indication, dosing, list price, and the practical consequences for patients and prescribers.